Labrys Biologics Inc. has picked up where Pfizer Inc. left off in developing a peripherally acting mAb for migraine. The therapeutic strategy is to hit a well-known pro-inflammatory target that turns sporadic migraine attacks into the debilitating chronic form of the disease.

Labrys' sole asset is RN-307, a mAb against calcitonin gene-related peptide (CGRP) that previously completed Phase I testing for chronic migraine. CGRP is a vasodilatory and pro-inflammatory peptide whose levels rise in the meningeal blood-brain interface during migraine onset, exacerbating pain and inflammation.